Cao X, Ling C, Liu Y, Gu Y, Huang J, Sun W
Animals (Basel). 2024; 14(18).
PMID: 39335310
PMC: 11428621.
DOI: 10.3390/ani14182721.
Tan Y, Yu Y, Niu H, Wang C, Mo P, Li D
Mol Biol Rep. 2024; 51(1):929.
PMID: 39172288
DOI: 10.1007/s11033-024-09861-3.
Yi G, Ye M, Carrique L, El-Sagheer A, Brown T, Norbury C
Nat Struct Mol Biol. 2024; 31(9):1426-1438.
PMID: 39054354
PMC: 11402785.
DOI: 10.1038/s41594-024-01357-9.
Zhuo Z, Lin L, Miao L, Li M, He J
Fundam Res. 2024; 2(6):903-917.
PMID: 38933377
PMC: 11197818.
DOI: 10.1016/j.fmre.2022.08.005.
Sheeter D, Garza S, Park H, Benhamou L, Badi N, Espinosa E
Cancers (Basel). 2024; 16(8).
PMID: 38672672
PMC: 11048984.
DOI: 10.3390/cancers16081590.
N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia.
Peramangalam P, Surapally S, Veltri A, Zheng S, Burns R, Zhu N
Sci Adv. 2024; 10(9):eadh8493.
PMID: 38416825
PMC: 10901375.
DOI: 10.1126/sciadv.adh8493.
Epigenetic Dysregulation in -Amplified Neuroblastoma.
Epp S, Chuah S, Halasz M
Int J Mol Sci. 2023; 24(23).
PMID: 38069407
PMC: 10707345.
DOI: 10.3390/ijms242317085.
Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development.
Yuan Y, Alzrigat M, Rodriguez-Garcia A, Wang X, Sjoberg Bexelius T, Johnsen J
Cancers (Basel). 2023; 15(18).
PMID: 37760568
PMC: 10527308.
DOI: 10.3390/cancers15184599.
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in -amplified neuroblastoma.
Zhang H, Delaidelli A, Javed S, Turgu B, Morrison T, Hughes C
Sci Adv. 2023; 9(34):eadg6693.
PMID: 37611092
PMC: 10446492.
DOI: 10.1126/sciadv.adg6693.
Neuroblastoma of the lumbosacral canal in an adult: a case report and literature review.
Jiang Q, Gao H, Gao G, Li Y, Cheng H, Shi G
Front Neurol. 2023; 14:1195664.
PMID: 37602246
PMC: 10435846.
DOI: 10.3389/fneur.2023.1195664.
The Epigenetic Landscape of Meningiomas.
Wang J, Nassiri F, Aldape K, von Deimling A, Sahm F
Adv Exp Med Biol. 2023; 1416:175-188.
PMID: 37432627
DOI: 10.1007/978-3-031-29750-2_13.
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review.
Tangella A, Gajre A, Chirumamilla P, Rathhan P
Cureus. 2023; 15(4):e37680.
PMID: 37206500
PMC: 10190116.
DOI: 10.7759/cureus.37680.
Small regulatory RNAs: from bench to bedside - a keystone symposia meeting report.
Lee S, Winters M, Martinez I, Slack F
RNA Biol. 2023; 20(1):136-139.
PMID: 37016725
PMC: 10078130.
DOI: 10.1080/15476286.2023.2196046.
Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.
Almeida J, Mota I, Skoda J, Sousa E, Cidade H, Saraiva L
Cancers (Basel). 2022; 14(24).
PMID: 36551697
PMC: 9777536.
DOI: 10.3390/cancers14246212.
MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma.
Liu T, Gu L, Wu Z, Albadari N, Li W, Zhou M
Front Oncol. 2022; 12:1058726.
PMID: 36505784
PMC: 9730801.
DOI: 10.3389/fonc.2022.1058726.
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.
Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P
Cancers (Basel). 2022; 14(18).
PMID: 36139583
PMC: 9496712.
DOI: 10.3390/cancers14184421.
Gain of Chromosome 1q Perturbs a Competitive Endogenous RNA Network to Promote Melanoma Metastasis.
Xu X, Wang K, Vera O, Verma A, Jasani N, Bok I
Cancer Res. 2022; 82(17):3016-3031.
PMID: 36052492
PMC: 9971359.
DOI: 10.1158/0008-5472.CAN-22-0283.
The function and regulatory mechanism of RNA-binding proteins in breast cancer and their future clinical treatment prospects.
Lu X, Zhong J, Liu L, Zhang W, Zhao S, Chen L
Front Oncol. 2022; 12:929037.
PMID: 36052258
PMC: 9424610.
DOI: 10.3389/fonc.2022.929037.
Precision Anti-Cancer Medicines by Oligonucleotide Therapeutics in Clinical Research Targeting Undruggable Proteins and Non-Coding RNAs.
Bartolucci D, Pession A, Hrelia P, Tonelli R
Pharmaceutics. 2022; 14(7).
PMID: 35890348
PMC: 9315662.
DOI: 10.3390/pharmaceutics14071453.
Mutations of 1p genes do not consistently abrogate tumor suppressor functions in 1p-intact neuroblastoma.
Kuick C, Tan J, Jasmine D, Sumanty T, Ng A, Venkatesh B
BMC Cancer. 2022; 22(1):717.
PMID: 35768791
PMC: 9245282.
DOI: 10.1186/s12885-022-09800-0.